{
    "Clinical Trial ID": "NCT00121836",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Capecitabine+Bevacizumab (Bev); Paclitaxel or Vinorelbine +Bev",
        "  First Study Treatment Phase:",
        "  Capecitabine 1000 mg/m\u00b2 oral (PO) twice-daily, Days 1-15 of each 3-week cycle (28 doses per cycle); bevacizumab 15 mg/kg intravenous (IV) infusion, Day 1 of each 3-week cycle.",
        "  Second Study Treatment Phase:",
        "  Paclitaxel 80 mg/m\u00b2 60-minute IV infusion (with appropriate premedication), Days 1, 8 and 15 of each 4-week cycle (28 days). Substitution of paclitaxel with docetaxel was not allowed.",
        "  Vinorelbine 25 mg/m\u00b2 IV infusion over 10-20 minutes, Days 1, 8, and 15 of each 4-week cycle.",
        "  Bevacizumab 10 mg/kg IV infusion, Days 1 and 15 of each 4-week cycle."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Women >=18 years of age",
        "  HER2-negative metastatic breast cancer",
        "  Previous adjuvant chemotherapy or hormonal treatment",
        "  >=1 measurable target lesion",
        "Exclusion Criteria:",
        "  Previous treatment with chemotherapy, an anti-angiogenic agent, or a biologic therapy for advanced or metastatic cancer",
        "  Radiation therapy within 4 weeks of study treatment start or insufficient recovery from the effects of prior radiation therapy",
        "  Central nervous system metastases",
        "  Other malignancy within last 5 years, except cured basal cell carcinoma of skin and carcinoma in situ of uterine cervix",
        "  Serious concurrent infection"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Overall Survival",
        "  Overall survival was defined as the time from date of first treatment dose (Day 1) to date of death, across the study phases regardless of the cause of death",
        "  Time frame: approximately 505 days (Median Time to Death)",
        "Results 1: ",
        "  Arm/Group Title: Capecitabine+Bevacizumab (Bev); Paclitaxel or Vinorelbine +Bev",
        "  Arm/Group Description: First Study Treatment Phase:",
        "  Capecitabine 1000 mg/m  oral (PO) twice-daily, Days 1-15 of each 3-week cycle (28 doses per cycle); bevacizumab 15 mg/kg intravenous (IV) infusion, Day 1 of each 3-week cycle.",
        "  Second Study Treatment Phase:",
        "  Paclitaxel 80 mg/m  60-minute IV infusion (with appropriate premedication), Days 1, 8 and 15 of each 4-week cycle (28 days). Substitution of paclitaxel with docetaxel was not allowed.",
        "  Vinorelbine 25 mg/m  IV infusion over 10-20 minutes, Days 1, 8, and 15 of each 4-week cycle.",
        "  Bevacizumab 10 mg/kg IV infusion, Days 1 and 15 of each 4-week cycle.",
        "  Overall Number of Participants Analyzed: 109",
        "  Median (95% Confidence Interval)",
        "  Unit of Measure: Days  505        (420 to 672)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 39/109 (35.78%)",
        "  Febrile Neutropenia1/109 (0.92%)",
        "  Left Ventricular Failure1/109 (0.92%)",
        "  Nausea3/109 (2.75%)",
        "  Vomiting3/109 (2.75%)",
        "  Abdominal Pain1/109 (0.92%)",
        "  Caecitis1/109 (0.92%)",
        "  Diarrhoea1/109 (0.92%)",
        "  Enterovesical Fistula1/109 (0.92%)",
        "  Gastric Ulcer1/109 (0.92%)",
        "  Pancreatitis1/109 (0.92%)",
        "  Pain6/109 (5.50%)",
        "  Chest Pain3/109 (2.75%)"
    ]
}